Microsaic Systems Share Discussion Threads

[k1ngkonggb] 15/1/2018 12:27

Stephen, you should have been on at Christmas with the two Ronnie's!!!!

[moneymunch] 15/1/2018 11:42

Lol Stephen, the last time you predicted that, the share price climbed to 4p plus ha ha ha.....Bring it on!!! ;-)

[stephen2010] 15/1/2018 11:33

Correction back to mid 2's as predicted.

[k1ngkonggb] 15/1/2018 11:04

It will be sometime before we get concrete news based on the recent events in Dec.

Still massively undervalued and this is definitely a med/longer term hold.

[dave4545] 15/1/2018 10:28

Yep chart is not too clever. It needs news now. I took a loss on my last trade here
but a small one. But market not as bullish as it was a few weeks ago and some star stocks can quickly become fish and chip paper without news. It's had a good run from the lows.

[moneymunch] 15/1/2018 10:27

This will ping up soon enough, I reckon. Gla ;-)

[2prsimo] 15/1/2018 10:20

chart rolling over unfortunately - needs news

[2prsimo] 15/1/2018 10:20

duplicate post

[k1ngkonggb] 15/1/2018 09:18

This may well have presented me with another buying opportunity....will it go lower!!!???

[moneymunch] 13/1/2018 11:30

Glenn Tracey, CEO of Microsaic Systems plc, commented: “We are delighted to agree this new phase of our collaboration with one of the foremost players in the global market for scientific instrumentation, which is in line with the Company’s strategy to focus on application areas in bioprocessing and diagnostics. Since our previous announcement in April, in cooperation with the partner, we have demonstrated the technical feasibility of a specific biopharma application, and established the interest of end users. In this most recent contracted phase, which is expected to last into H2 2018, we will work closely with the partner to further integrate our MS technology with their world leading purification equipment. Our goal is that this will be followed by full product development and launch. If this goal is realised, we estimate that this product alone will represent a major commercial opportunity for Microsaic. Additionally, we will be evaluating other potential applications with this partner.

“I am pleased that with this extension and deepening of our collaboration, our partner is demonstrating confidence both in Microsaic’s MS technology, and in the potential of miniature MS in the bioprocessing industry.”

[moneymunch] 13/1/2018 11:27

One step ahead!!! Gla ;-)


Offering the smallest footprint in the market, the 4000 MiD is a fully integrated, versatile, miniature mass spectrometry system designed for bench chemists.

The 4000 MiD is the only mass spectrometer to contain everything in one box, including PC and all pumps. The core technologies are chip-scale, ‘plug and play’ versions of traditional mass spectrometry components which can be interchanged rapidly by the user. Its easy integration, low operating cost and small footprint make the 4000 MiD deployable in a wide range of applications where mass spectrometry has not been able to reach – until now.

[moneymunch] 13/1/2018 11:26

4. Looking to the future, how do you think LC–MS can be developed further? What techniques do you think are next to advance the field further?

Optimal LC–MS results are currently obtained from users who really know how to do good HPLC and who understand mass spectrometry and the vagaries of electrospray and APCI. Unfortunately, LC–MS is not yet as simple as driving a modern, high technology automobile where the driver only needs to know the rules of the road; e.g. the driver does not need to understand the engine, transmission or the ignition system. He or she just ‘pushes the starter button’ and drives off. We are not yet there with LC–MS, but we can be in the future. Future LC–MS systems need to be a ‘black box’ such that the operator can be anyone; not an expert. This trend is occurring as LC–MS is entering the clinical and forensic laboratories where thousands of samples are run regularly by non-specialists.

5. Are there any researchers/projects/technologies that you are watching at the moment, and who should we be keeping an eye on?

There are still many opportunities for improvements and advancements. Miniaturization is important and is occurring. Small, compact mass spectrometers are being developed. Advion has introduced a compact mass spectrometer amenable to LC–MS as well as facile ‘sniffing’ applications for rapid screening of breath and/or volatile sample head space analyses. 908 Devices has a hand-held mass spectrometer as well as a CE/MS interface which compliments LC–MS analyses. Integration of the HPLC with MS must be transparent and not involve an ‘interface’ which can often be the weak link in the system.

The best interface is no interface! Simplicity of operation is the key to wider acceptance and should follow the intuitive ease-of-use nature common to iPhones and home entertainment systems. The cost of mass spectrometers must be lowered to make it more widely available such as in a police cars for roadside applications as well as being amenable, for example, to analysis by a certified cannabis grower to monitor the potency of the cannabis crop. There are many areas where LC–MS and mass spectrometry in general could be used but is not currently due to cost and complexity of the experiments.

Finally, the drugs of the future will be large molecule biotherapeutics which will require catabolism characterization as well as their quantitative determination from biological samples. The sensitivity and selectivity of LC–MS techniques will certainly be needed to help bring these novel entities to market as safe and effective drugs.

Since the pharmacological effectiveness of biotherapeutics will be the result of their native conformation in vivo, it will be important to demonstrate that we are analyzing the intact, native species to ensure we truly are measuring what was important in the dose/response process. Lastly, high resolution mass spectrometry has added tremendous analytical horsepower to LC–MS capabilities.

However, in contrast to the points above, the orbitraps and QTOF’s of the future must be lower cost to allow wider use to the ‘masses’. The future of LC–MS will be exciting as novel and creative technology developments occur.

[elcapital20i7] 12/1/2018 15:19

We love moneymunch!!!

[moneymunch] 12/1/2018 13:42

Cheers, that's basically a whole new team they're looking to recruit, presumably in anticipation of increased production and development of their existing and/or new technology...all bodes well. Gl ;-)

[moneymunch] 12/1/2018 13:29

Current roles available

Project Manager
Principal Scientist
Senior Scientist
Senior Software Engineer
Product Development Engineer

[moneymunch] 12/1/2018 13:26

A very good sign imho...Gla ;-)

Microsaic
‏ @Microsaic
2h2 hours ago

We're recruiting scientists and engineers! See our careers page:

#massspec #biologics #bioprocessing
0 replies 1 retweet 1 like

[moneymunch] 12/1/2018 11:51

Lol splatted, no worries...there are plenty out there who appear to judge me by their own standards...my intention is to hold to disclosure of Microsaic's global biopharma....in the meantime time, impatiently patiently awaiting the next positive Rns and a big jump in share price Gl :-)

[splatted] 12/1/2018 11:46

Oooh top up time approaching;-)))

[splatted] 12/1/2018 11:25

I think an apology is owed moneymunch. Humble pie in the post

[moneymunch] 12/1/2018 11:03

Q1: Microsaic recently announced the signing of a research agreement with a global partner in biopharma, can you tell us a little bit more about that?

A1: Yes, absolutely so I’ve got to say that we are under strict NDA in this particular case but what I can do is give you some context. Earlier in the year we successfully completed a significant joint feasibility phase to show dedicated at-line mass spec can assess the quality of biologics during the manufacture.

I think perhaps the most important aspect of that phase was that we had substantial end-user validation from big pharma and just to say that these are end-users whom our partner has very good global reach.

What this new phase is it will bring more end-user validation to the approach, but I think the exciting deliverable is that we’ll be able to provide a lot more technical integration with the partner’s product.

So, should this activity be successful, it will take us into the second half of 2018 and then that will proceed a period of productisation. As I said, I can’t give any details yet about the size and timeline for commercialisation, but the opportunity is significant to us, to Microsaic, and delivery is proportionate, I would say, to our timescales.